Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

FDA approves drug to reduce risk of HER2-positive breast cancer returning

The US Food and Drug Administration has approved neratinib (Nerlynx; Puma Biotechnology), a kinase inhibitor that blocks enzymes that promote cell growth, for early-stage, HER2-positive breast cancer